Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management

Vivek P. Chavda; Lalitkumar K. Vora; Anjali K. Pandya; Vandana B. Patravale

doi:10.1016/j.drudis.2021.07.021

Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management

Vivek P. Chavda^*, Lalitkumar K. Vora^*, Anjali K. Pandya, Vandana B. Patravale

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

167 Citations (Scopus)

Abstract

Unlike conventional Coronavirus 2019 (COVID-19) vaccines, intranasal vaccines display a superior advantage because the nasal mucosa is often the initial site of infection. Preclinical and clinical studies concerning intranasal immunization elicit high neutralizing antibody generation and mucosal IgA and T cell responses that avoid severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in both; the upper and lower respiratory tract. A nasal formulation is non-invasive with high appeal to patients. Intranasal vaccines enable self-administration and can be designed to survive at ambient temperatures, thereby simplifying logistical aspects of transport and storage. In this review, we provide an overview of nasal vaccines with a focus on formulation development as well as ongoing preclinical and clinical studies for SARS-CoV-2 intranasal vaccine products.

Original language	English
Pages (from-to)	2619-2636
Number of pages	18
Journal	Drug Discovery Today
Volume	26
Issue number	11
Early online date	29 Jul 2021
DOIs	https://doi.org/10.1016/j.drudis.2021.07.021
Publication status	Published - 01 Nov 2021

Bibliographical note

Funding Information:
Figs. 1 and 2 were prepared using templates from BioRender.com. A.K.P. would like to thank the Department of Science & Technology (DST) INSPIRE program of the Ministry of Science & Technology, Government of India, for providing her fellowship. V.B.P. would like to acknowledge DBT BIRAC COVID-19 Research Consortium, Government of India, for her grant to work toward the development of an intranasal mucosal vaccine for COVID-19 infection (BT/PR40394/COV/140/1/2020).

Funding Information:
Anjali Pandya is a recipient of a doctoral fellowship at the Institute of Chemical Technology, Mumbai, India, awarded by the Department of Science and Technology (DST) - Innovation in Science Pursuit for Inspired Research (INSPIRE), Government of India, for research on oral protein and peptide delivery,.

Publisher Copyright:
© 2021 Elsevier Ltd

Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.

Keywords

Antigen-presenting cells (APCs)
COVID-19
Dendritic cells
Nasal spray
Nasal vaccine
SARS-CoV-2

ASJC Scopus subject areas

Pharmacology
Drug Discovery

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.drudis.2021.07.021Licence: Unspecified

Cite this

@article{83971d66c0aa4eca85326ea59deebc40,

title = "Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management",

abstract = "Unlike conventional Coronavirus 2019 (COVID-19) vaccines, intranasal vaccines display a superior advantage because the nasal mucosa is often the initial site of infection. Preclinical and clinical studies concerning intranasal immunization elicit high neutralizing antibody generation and mucosal IgA and T cell responses that avoid severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in both; the upper and lower respiratory tract. A nasal formulation is non-invasive with high appeal to patients. Intranasal vaccines enable self-administration and can be designed to survive at ambient temperatures, thereby simplifying logistical aspects of transport and storage. In this review, we provide an overview of nasal vaccines with a focus on formulation development as well as ongoing preclinical and clinical studies for SARS-CoV-2 intranasal vaccine products.",

keywords = "Antigen-presenting cells (APCs), COVID-19, Dendritic cells, Nasal spray, Nasal vaccine, SARS-CoV-2",

author = "Chavda, {Vivek P.} and Vora, {Lalitkumar K.} and Pandya, {Anjali K.} and Patravale, {Vandana B.}",

note = "Funding Information: Figs. 1 and 2 were prepared using templates from BioRender.com. A.K.P. would like to thank the Department of Science & Technology (DST) INSPIRE program of the Ministry of Science & Technology, Government of India, for providing her fellowship. V.B.P. would like to acknowledge DBT BIRAC COVID-19 Research Consortium, Government of India, for her grant to work toward the development of an intranasal mucosal vaccine for COVID-19 infection (BT/PR40394/COV/140/1/2020). Funding Information: Anjali Pandya is a recipient of a doctoral fellowship at the Institute of Chemical Technology, Mumbai, India, awarded by the Department of Science and Technology (DST) - Innovation in Science Pursuit for Inspired Research (INSPIRE), Government of India, for research on oral protein and peptide delivery,. Publisher Copyright: {\textcopyright} 2021 Elsevier Ltd Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2021",

month = nov,

day = "1",

doi = "10.1016/j.drudis.2021.07.021",

language = "English",

volume = "26",

pages = "2619--2636",

journal = "Drug Discovery Today",

issn = "1359-6446",

publisher = "Elsevier Ltd",

number = "11",

}

TY - JOUR

T1 - Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management

AU - Chavda, Vivek P.

AU - Vora, Lalitkumar K.

AU - Pandya, Anjali K.

AU - Patravale, Vandana B.

N1 - Funding Information: Figs. 1 and 2 were prepared using templates from BioRender.com. A.K.P. would like to thank the Department of Science & Technology (DST) INSPIRE program of the Ministry of Science & Technology, Government of India, for providing her fellowship. V.B.P. would like to acknowledge DBT BIRAC COVID-19 Research Consortium, Government of India, for her grant to work toward the development of an intranasal mucosal vaccine for COVID-19 infection (BT/PR40394/COV/140/1/2020). Funding Information: Anjali Pandya is a recipient of a doctoral fellowship at the Institute of Chemical Technology, Mumbai, India, awarded by the Department of Science and Technology (DST) - Innovation in Science Pursuit for Inspired Research (INSPIRE), Government of India, for research on oral protein and peptide delivery,. Publisher Copyright: © 2021 Elsevier Ltd Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021/11/1

Y1 - 2021/11/1

N2 - Unlike conventional Coronavirus 2019 (COVID-19) vaccines, intranasal vaccines display a superior advantage because the nasal mucosa is often the initial site of infection. Preclinical and clinical studies concerning intranasal immunization elicit high neutralizing antibody generation and mucosal IgA and T cell responses that avoid severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in both; the upper and lower respiratory tract. A nasal formulation is non-invasive with high appeal to patients. Intranasal vaccines enable self-administration and can be designed to survive at ambient temperatures, thereby simplifying logistical aspects of transport and storage. In this review, we provide an overview of nasal vaccines with a focus on formulation development as well as ongoing preclinical and clinical studies for SARS-CoV-2 intranasal vaccine products.

AB - Unlike conventional Coronavirus 2019 (COVID-19) vaccines, intranasal vaccines display a superior advantage because the nasal mucosa is often the initial site of infection. Preclinical and clinical studies concerning intranasal immunization elicit high neutralizing antibody generation and mucosal IgA and T cell responses that avoid severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in both; the upper and lower respiratory tract. A nasal formulation is non-invasive with high appeal to patients. Intranasal vaccines enable self-administration and can be designed to survive at ambient temperatures, thereby simplifying logistical aspects of transport and storage. In this review, we provide an overview of nasal vaccines with a focus on formulation development as well as ongoing preclinical and clinical studies for SARS-CoV-2 intranasal vaccine products.

KW - Antigen-presenting cells (APCs)

KW - COVID-19

KW - Dendritic cells

KW - Nasal spray

KW - Nasal vaccine

KW - SARS-CoV-2

U2 - 10.1016/j.drudis.2021.07.021

DO - 10.1016/j.drudis.2021.07.021

M3 - Review article

AN - SCOPUS:85112498826

SN - 1359-6446

VL - 26

SP - 2619

EP - 2636

JO - Drug Discovery Today

JF - Drug Discovery Today

IS - 11

ER -

Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Fingerprint

Cite this